Article

Enhancing precision medicine for patients with breast cancer brain metastases through functional drug testing

2026-04-22

Abstract excerpt

Patient-derived organoids from breast cancer brain metastases enable real-time drug sensitivity testing integrated with genomic profiling. Drug response varied by subtype and molecular alterations. PI3K inhibitors showed activity regardless of PIK3CA mutation status. Pronounced tumor heterogeneity highlighted the urgent need for effective therapies personalized for each patient. Functional assays and molecular mat...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 473f0756-cd1a-5394-a023-7d577a847847
DOI: 10.64898/2026.04.18.719400

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Enhancing precision medicine for patients with breast cancer brain metastases through functional drug testingDOI 10.64898/2026.04.18.719400Read

Functional Drug Screening in the Era of Precision MedicineSemantic proximity Read

Systematic functional drug testing in patient-derived models reveals ex vivo sensitivities associated with clinical outcome in rare solid tumorsSemantic proximity Read

Molecular Oncodiagnostics in Precision Oncology: Integrating Tumor Transcriptomics, Patient Pharmacogenetics, and Ex Vivo Chemoresistance Testing to Improve Individual Chemotherapy ResponseSemantic proximity Read

Breast cancer patient-derived microtumors resemble tumor heterogeneity and enable protein-based stratification and functional validation of individualized drug treatmentSemantic proximity Read

Incorporating tumor genomic profiling and drug screening through circulating tumor cell- derived organoids into clinical practice for the management of Gastrointestinal CancersSemantic proximity Read

Personalized pharmacokinetic-pharmacodynamic guided therapy via an induced pluripotent stem cell-derived multi-organoid platform in NF1-mutant breast cancer.Semantic proximity Read

Pancreatic cancer patient-derived organoids capture therapy response and tumor evolutionSemantic proximity Read

Organoid-evaluable clinical biomarkers predict drug responses and guide new breast cancer therapiesSemantic proximity Read

Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug ResponsesSemantic proximity Read

Will Organoids Fill the Gap towards Functional Precision Medicine?Semantic proximity Read

Genomic profiling using the UltraSEEK panel identifies discordancy between paired primary and breast cancer brain metastases and an association with brain metastasis-free survival.Semantic proximity Read

Re-Evaluating Breast Malignant Pleural Effusion: Toward Evidence-Based, Precision-Aligned Care with OrganoidsSemantic proximity Read